• Log In or Create Account
  • CROI
  • Conference on Bacteriophages
  • RWHAP CLINICAL CONFERENCE
  • Podcasts
  • Slides
  • Question of the Week
  • Guidelines
  • Contact
Advanced Search
Investigational HIV Drugs and Emergent Strategies - IAS-USA
  • CME Courses
    • HIV In-Person and Virtual Courses
    • Current On-Demand Courses
    • About Courses
  • CME Webinars
    • Upcoming Webinars
    • Current On-Demand Webinars
    • MATE Act CME
    • About Webinars
  • Dialogues
    • Upcoming IAS–USA Dialogues: Emerging Infections and Health Threats
    • On-Demand Dialogues
    • About Dialogues
  • Topics In Antiviral Medicine
    • Current Issues for CME
    • Previous Issues
    • TAM Policies and Practices
    • Permission Request Form
  • HIV Drug Resistance
    • HIV Drug Resistance Resources
    • HIV Drug Resistance Mutations Chart
    • Recent Webinars
    • Journal Articles
  • Fellow Resources
    • Resources for Fellows and Others New to the HIV Field
    • On-Demand Webinars for Fellows
    • IAS-USA Guidelines and Recommendations
    • On-Demand Webcasts
    • Research Collaborations
    • Additional Resources
  • About
    • Scientific Leadership Board
    • IAS-USA Leadership Award Recipients
    • Core Faculty
    • Mission
    • Staff
    • CME
    • Funding Information
    • Careers
    • Website Policies
    • Discrimination and Harassment Policy
    • Governance
    • Suggestions and Recommendations from San Francisco Locals
    • Donate
    • FAQs

Investigational HIV Drugs and Emergent Strategies

Investigational HIV Drugs and Emergent Strategies

Investigational HIV Drugs and Emergent Strategies
Presenter: Roy M. Gulick, MD, MPH

Slides

On-Demand Webcast

Podcast

iasusa · 8-Investigational HIV Drugs and Emergent Strategies

Investigational HIV Drugs and Emergent Strategies - IAS-USA

131 Steuart St, Suite 500, San Francisco, CA 94105

Phone: (415) 544-9400 | info@iasusa.org

  • Home
  • Activities
  • Resources
  • About
  • Contact
  • Login
  • Careers
  • Donate
  • Website Policies
© 2026 International Antiviral Society–USA. All Rights Reserved.
  • CROI
  • Conference on Bacteriophages
  • RWHAP CLINICAL CONFERENCE
  • Podcasts
  • Slides
  • Question of the Week
  • Guidelines
  • Contact
  • CME Courses
    • HIV In-Person and Virtual Courses
    • Current On-Demand Courses
    • About Courses
  • CME Webinars
    • Upcoming Webinars
    • Current On-Demand Webinars
    • MATE Act CME
    • About Webinars
  • Dialogues
    • Upcoming IAS–USA Dialogues: Emerging Infections and Health Threats
    • On-Demand Dialogues
    • About Dialogues
  • Topics In Antiviral Medicine
    • Current Issues for CME
    • Previous Issues
    • TAM Policies and Practices
    • Permission Request Form
  • HIV Drug Resistance
    • HIV Drug Resistance Resources
    • HIV Drug Resistance Mutations Chart
    • Recent Webinars
    • Journal Articles
  • Fellow Resources
    • Resources for Fellows and Others New to the HIV Field
    • On-Demand Webinars for Fellows
    • IAS-USA Guidelines and Recommendations
    • On-Demand Webcasts
    • Research Collaborations
    • Additional Resources
  • About
    • Scientific Leadership Board
    • IAS-USA Leadership Award Recipients
    • Core Faculty
    • Mission
    • Staff
    • CME
    • Funding Information
    • Careers
    • Website Policies
    • Discrimination and Harassment Policy
    • Governance
    • Suggestions and Recommendations from San Francisco Locals
    • Donate
    • FAQs
Practice Question of the Week

October 26, 2026: Body Composition and Cardiovascular Risk Reduction With GLP-1 Receptor Agonists

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been shown to both decrease weight and decrease cardiovascular events in people with and without diabetes. In people without diabetes, what proportion of the cardiovascular risk reduction is attributable to changes in body composition?
View the On-Demand Course
View Archived Questions
Leave Feedback
Subscribe